Fig. 1From: Novel quinazolines bearing 1,3,4-thiadiazole-aryl urea derivative as anticancer agents: design, synthesis, molecular docking, DFT and bioactivity evaluationsStructures of FDA-approved EGFR and VEGFR-2 inhibitor drugs featuring quinazoline, thiadiazole, and urea moietiesBack to article page